Research identifies a way to make cancer cells more responsive to chemotherapy

May 23, 2013

Breast cancer characterized as "triple negative" carries a poor prognosis, with limited treatment options. In some cases, chemotherapy doesn't kill the cancer cells the way it's supposed to. New research from Western University explains why some cancer cells don't respond to chemotherapy, and identifies a mechanism to rectify that.

Dr. Shawn Li, PhD, and his team at Western's Schulich School of Medicine & Dentistry, identified that a protein called Numb functions to promote the death of cancer cells by binding to and stabilizing a tumor suppressor protein called p53 -a master regulator of cell death. The scientists found when Numb is reduced or methylated by an enzyme called Set8, it will no longer protect p53. The research is published in the May 23rd issue of Molecular Cell. A related research paper on the role of chemotherapeutic agents on regulating protein methylation, also from the Li lab, will be published in the June 7th issue of Molecular Cell, and is now online.

The video will load shortly
New research from Western University explains why some cancer cells don't respond to chemotherapy, and identifies a mechanism to rectify that. Dr. Shawn Li, Ph.D., explains how a protein called Numb functions to promote the death of cancer cells by binding to and stabilizing a tumor suppressor protein called p53. When Numb is reduced or methylated by an enzyme called Set8, it will no longer protect p53, and the cells become resistant to chemotherapy. Credit: Schulich School of Medicine & Dentistry, Western University

"If you don't have Numb in a cell, then the p53 can be degraded very quickly, and these cells become resistant to chemotherapy," explains Li, a professor of Biochemistry and Canada Research Chair in Cellular Proteomics and Functional Genomics. "So if we can prevent Numb from being methylated in , then we will have the means to sensitize the cell to chemotherapy."

Now that he's identified the Set8-Numb-p53 pathway, Li is investigating various drugs to find a Set8 inhibitor which could be used as a novel therapy alone, or in combination with other regiments.

Explore further: Normal gene hinders breast cancer chemotherapy

Related Stories

Normal gene hinders breast cancer chemotherapy

June 11, 2012

Presence of normal p53, a tumor suppressor gene, instead of a mutated version, makes breast cancer chemotherapy with doxorubicin less effective. The preclinical study led by MD Anderson scientists was published today in the ...

Wip1 could be new target for cancer treatment

May 6, 2013

Researchers have uncovered mutations in the phosphatase Wip1 that enable cancer cells to foil the tumor suppressor p53, according to a study in The Journal of Cell Biology. The results could provide a new target for the treatment ...

Recommended for you

Beneficial bacteria may protect breasts from cancer

June 24, 2016

Bacteria that have the potential to abet breast cancer are present in the breasts of cancer patients, while beneficial bacteria are more abundant in healthy breasts, where they may actually be protecting women from cancer, ...

Aggressiveness of acute myeloid leukemia elucidated

June 24, 2016

Antoine Peters and colleagues at the Basel University Children's Hospital (UKBB) have discovered why acute leukemias with the same genetic abnormality vary in their aggressiveness based on their cellular origin. They found ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.